Pharma licensing deals soared to record $46.2 billion 2015, report shows

17 June 2016

The value of licensing deals in the pharmaceutical industry increased by 37.1% to $46.2 billion in 2015, according to research and consulting firm GlobalData.

This rise of $12.5 billion from the $33.7 billion total in 2014 was due primarily to the activity of French pharma major Sanofi (Euronext: SAN), which struck three licensing deals that totaled nearly $9 billion.

These included the sizeable $4.3 billion partnership with South Korea’s Hanmi Pharma (128940: KS) to develop a portfolio of experimental, long-acting diabetes treatments.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK